In the present study, we investigated the mechanism of CD44 ligation with the anti-CD44 monoclonal antibody A3D8 to inhibit the proliferation of human acute myeloid leukemia (AML) cells. The effects of A3D8 on myeloid cells were associated with specific disruption of cell cycle events and induction of G0/G1 arrest. Induction of G0/G1 arrest was accompanied by an increase in the expression of p21, attenuation of pRb phosphorylation and associated with decreased Cdk2 and Cdk4 kinase activities. Since c-Jun is an important regulator of proliferation and cell cycle progression, we analysed its role in A3D8-mediated growth arrest. We observed that A3D8 treatment of AML patient blasts and HL60/U937 cells led to the downregulation of c-Jun expression at mRNA and protein level. Transient transfection studies showed the inhibition of c-jun promoter activity by A3D8, involving both AP-1 sites. Furthermore, A3D8 treatment caused a decrease in JNK protein expression and a decrease in the level of phosphorylated c-Jun. Ectopic overexpression of c-Jun in HL60 cells was able to induce proliferation and prevent the antiproliferative effects of A3D8. In summary, these data identify an important functional role of c-Jun in the induction of cell cycle arrest and proliferation arrest of myeloid leukemia cells because of the ligation of the cell surface adhesion receptor CD44 by anti-CD44 antibody. Moreover, targeting of G1 regulatory proteins and the resulting induction of G1 arrest by A3D8 may provide new insights into antiproliferative and differentiation therapy of AML.
Introduction
Acute myeloid leukemia (AML) is characterized by a block in differentiation (Tenen et al., 1997) . The proliferative activity of leukemic blasts is maintained leading to the accumulation of malignant cells and a suppression of normal hematopoiesis (Tenen et al., 1997; Lowenberg et al., 1999) . In experimental systems, and in specific clinical settings such as in acute promyelocytic leukemia, the differentiation block can be overcome and leukemic cells can terminally differentiate after exposure to either chemical agents (Kantarjian, 1999) or by use of monoclonal antibodies (both conjugated and unconjugated) that target antigens on leukemic blasts (Sievers, 2000; Waxman, 2000) . Among the various antigens that could serve as targets of antibody-mediated differentiation, the adhesion receptors, such as CD44, deserve considerable attention in view of their role in transmitting signals that can modulate cell proliferation, survival and differentiation as well as their prevalence among leukemic cells (ReussBorst et al., 1992; Liesveld et al., 1994; Moll et al., 1998; Verfaillie, 1998) .
A compelling body of evidence suggests outside-in signaling through CD44 (Sanford et al., 1998; Lowell and Berton, 1999) when ligated with its natural ligand, hyaluronic acid (Aruffo et al., 1990; Miyake et al., 1990) or with specific monoclonal antibodies (MoAbs). Recent reports have suggested that ligation of CD44 by anti-CD44 MoAbs (e.g. A3D8) has antiproliferative and differentiation-inducing effects on myeloid cell lines and AML patient blasts in all AML subtypes (Allouche et al., 2000; Charrad et al., 1999) . However, the underlying molecular mechanisms remain largely unknown. In this study, we assessed the ability of the anti-CD44 MoAb A3D8 to modulate the expression of c-Jun and cell cycle regulatory molecules in the human myeloid leukemia cell lines HL60 and U937. We focused our attention on c-Jun, since it is implicated in the regulation of cell proliferation and cell cycle progression (Kovary and Bravo, 1991; Smith and Prochownik, 1992; Schreiber et al., 1999; Wisdom et al., 1999; Bakiri et al., 2000; Shaulian and Karin, 2001) . Although the role c-Jun in myeloid cells has been largely studied with respect to differentiation Rangatia et al., 2002; Vangala et al., 2002) , the role of c-Jun in A3D8-mediated growth arrest in human myeloid leukemia cells has not been analysed before. Moreover, at present there are only a few data regarding the influence of c-Jun on cell proliferation and cell cycle progression in myeloid cells. Consequently, it would be of interest to investigate the role of c-Jun and cell cycle regulatory molecules in parallel to further strengthening our knowledge on this ubiquitous transcription factor. Our recent data (Elsa¨sser et al., 2002; Rangatia et al., 2002) suggests that c-Jun expression might be a key event in the decision of a myeloid cell to differentiate or to proliferate. A mechanistic link between c-Jun and cell cycle in fibroblasts has been reported (Hilberg and Wagner, 1992; Milde-Langosch et al., 2000) .
The cell cycle machinery as such, is a highly coordinated process in which cyclins, cyclin-dependent kinases (Cdks) and their inhibitors (CDKIs) are differentially regulated (Muller et al., 1993; Matsushime et al., 1994; Sherr, 1994; Gitig and Koff, 2000) . Each cyclin can associate with one or more of the Cdk family, of which at least Cdk2 and Cdk4 kinase activities have been shown to operate in the G1 phase (Bates et al., 1994; Meyerson and Harlow, 1994) . The activity of G1 cyclin-Cdk complexes is regulated, at least in part, by CDKIs. Evidence is accumulating that CDKIs are targets of extracellular and intracellular signals that regulate cell growth and differentiation (Harper et al., 1993a, b; Hilberg et al., 1993; Nead et al., 1998; Nishitani et al., 1999; Steinman et al., 1994) . Based on these data and in the present study, we provide evidence that growth inhibition by CD44 ligation with A3D8 in myeloid leukemia cells is mediated through its effect on c-Jun expression. This is the first report providing a link between c-Jun and cell cycle in CD44-mediated growth arrest of myeloid leukemia cells.
Results

CD44 ligation inhibits the proliferation and induces terminal differentiation of myeloid leukemia cells
Treatment of HL60 (myeloblastic) and U937 (monoblastic) cells with the anti-CD44 MoAb antibody A3D8 for the time points as indicated in figure legends resulted in a dramatic decrease of proliferation (Figure 1 ). We performed the nonradioactive quantification of cell proliferation and cell viability (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay) for investigating the proliferation state of HL60 ( Figure 1a ) and U937 cells (Figure 1c) . The decreased proliferation of these myeloid cells also correlated with decreased CD71 (transferrin receptor) expression (Figure 1b, d ). CD71 is known to be a proliferation marker (Theil, 1990; Kuhn, 1994; Trayner et al., 1998) . Upon CD44 ligation by A3D8 in HL60 and U937 cells, we observed a drastic decrease in CD71 expression (47 and 7%, respectively) compared to the controls. It is important to note that CD71 expression was higher in HL60 cells (>90%, Figure 1b , upper left panel) as compared to U937 cells (o20%, Figure 1d , upper left panel). No inhibitory effect was observed with the isotype-matched MoAb control. Our results are in support of the recent observation that A3D8 has antiproliferative effect on myeloid cell lines (Charrad et al., 2002) .
To rule out the possibility of a cytotoxic effect of A3D8, we performed differentiation studies. Treatment of human myeloid HL60 and U937 cells with CD44 signaling inactivates c-Jun AA Peer Zada et al A3D8-induced striking changes in the morphology of these cells characteristic of terminal differentiation (Figure 2a, c) . For example, A3D8-treated cells showed decreased nucleus: cytoplasm ratios, segmented nuclei, few nucleoli and chromatin condensation. The effects like the formation of aggregates in culture and adherence became visible only after 12-18 h of A3D8 treatment. We also analysed the expression of the cell differentiation marker CD11b in HL60 and U937 cells (Figure 2b, d) and observed that its expression was increased in both cell lines after CD44 ligation. The expression of CD11b increased to B31% after A3D8 treatment compared to unstimulated (B7%) and isotype control (B9.6%) in HL60 cells (Figure 2b , upper left panels). Corresponding to this, the D-value (calculated as described in the Materials and methods) was found to be À57 after A3D8 treatment in HL60 cells compared to +30 for the control (Table 1) . In U937 cells, the expression of CD11b increased to B22% after A3D8 treatment compared to unstimulated (B6%) and isotype control (B7%) (Figure 2d , upper left panels). Corresponding to this, the D-value was found to be À78 after A3D8 treatment in U937 cells compared to +30 for the control (Table 1) .
CD44 ligation with A3D8 induces a G0/G1 arrest in myeloid leukemia cell lines
Cell cycle arrest is a common feature of cells undergoing terminal differentiation and defective proliferation. Based on the growth inhibitory and differentiationinducing effects of A3D8 on myeloid leukemia cell lines, we investigated their cell cycle progression in response to A3D8. The DNA content analysis showed that the myeloid cells underwent a G0/G1 arrest ( Figure 3) . Surprisingly, we observed a change in cell cycle distribution at 6 h of A3D8 treatment in HL60 cells as compared to untreated cells or cells treated with the isotype antibody. The proportion of cells in G0/ G1 phase increased from 54% (controls) to 67% in A3D8-treated cells after 24 h (Figure 3a ). This was mirrored by a decrease in the proportion of cells in the S and G2 phase from 13% (controls) to 2% in A3D8-treated cells and from 23% (controls) to 4% in A3D8-treated cells, respectively. The effect of A3D8 on cell cycle was dose dependent (Figure 3b ). In accordance with the induction of terminal differentiation by A3D8, we observed 14-27% of dead cells after 36 h. These data suggest that the growth inhibitory effect of A3D8 on myeloid cells is, in part, because of its effect on cell cycle progression.
CD44 ligation with A3D8 induces the expression of p21 and downregulates the expression of major G1 regulatory proteins
Based on the effects of A3D8 on G1 phase accumulation, we hypothesized the role of major G1 regulatory proteins. We examined the effect of A3D8 on p21, pRb, cyclin D1, cyclin D2, Cdk2, Cdk4 and Cdk6 protein expression. Our results show that A3D8 treatment of HL60 cells caused marked upregulation of p21 protein expression after 6 h ( Figure 4a , lane 3). The increased p21 protein level persisted for 12 h and was undetectable thereafter. The p21 level was undetectable in untreated or isotype-treated cells (Figure 4a , lanes 1 and 2). Since HL60 cells are p53 negative because of homozygous deletions (Steinman et al., 1998) , it is conceivable that p21 induction by A3D8 is p53 independent. Our results also show that treatment of HL60 cells with A3D8 for 12 and 24 h markedly decreases the expression of pRb ( Figure 4e ). It is important to note the presence of a slow migrating band (upper band) and a faster migrating band (lower band) when the blot was probed with antiRb antibody. The upper band corresponds to the hyperphosphorylated (*) form, while the lower band corresponds to the hypophosphorylated form (Slack et al., 1993; Savatier et al., 1994) . Inhibition of pRb correlated with decreased levels of Cdk2 and Cdk4 (Figure 4b , c). There was no effect on Cdk6 expression ( Figure 4d ), a little downregulation effect on cyclin D1 expression and no effect on the expression on cyclin D2 (data not shown).
CD44 ligation with A3D8 inhibits Cdk4 and Cdk2 activities
Cdk4 and Cdk2 kinase activities have been shown to operate in the G1 phase. G0/G1 arrest by A3D8 led us to analyse the kinase activities associated with these Cdks. Antibodies against Cdk4 and Cdk2 were used to perform immunocomplex kinase assays using recombinant Rb fusion protein and purified histone H1 protein as substrates, respectively. Consistent with its effect on cell cycle progression, A3D8 treatment inhibited Cdk4 and Cdk2 kinase activities (Figure 4g , h). The densitometry analysis showed that A3D8 treatment after 24 h caused greater than fourfold inhibition of Cdk4 kinase activity. Interestingly, Cdk2 kinase activity showed similar results. To normalize for the immunoprecipitation (IP) efficiency, a Western blot for respective Cdks was also performed after IP. IgG served as IP control. The results (Figure 4g , h) clearly show the specificity of our kinase reaction and that Cdk2 and Cdk4 were not degraded during the kinase reaction. It is important to note here that it might seem surprising to correlate Cdk activity with Rb phosphorylation after A3D8 treatment ( Figure 4e ) in which Rb IF8 (anti-mouse, sc-102) was used. However, this is not the case. Western blot of the lysates when probed with phospho-specific Rb antibody (pRb Ser-780, sc-12901, Santa Cruz) gave the expected results. Our results show that treatment of the cells with A3D8 led to decreased Rb phosphorylation (Figure 4f ), thereby correlating with decreased Cdk activity. The difference in the two results could thus, be attributed to antibody specificities. These data suggest that induction of G0/G1 arrest by A3D8 in myeloid cells may involve p21 induction and/or inhibition of Cdk activity. The AP-1 transcription factor c-Jun functions as a proliferation-promoting gene and is involved in cell cycle progression. Consequently, the expression of c-Jun would be expected to change in response to decreased proliferation and cell cycle arrest of HL60 and U937 cells upon CD44 ligation with A3D8. Our results show that there is a drastic decrease in c-jun mRNA expression ( Figure 5a , b) upon A3D8 treatment of the myeloid cells, c-jun expression was also downregulated in AML patient blasts after 6 and 12 h of A3D8 treatment in vitro ( Figure 5c ). We also observed a dramatic decrease in c-Jun protein expression upon CD44 ligation (Figure 5d ,e). It is important to note that there is a higher basal level of c-Jun expression in HL60 cells than in U937 cells (Figure 5d , e, unstimulated lanes). The amount of protein loaded in U937 blot ( Figure 5e ) was at least three times that of HL60 cells (Figure 5d ). To rule out a general toxic effect, we show that the expression of c-Fos (Figure 5f ) is not altered in a similar fashion. These data suggest that the downregulation of c-Jun contributes to A3D8-mediated growth arrest in myeloid cells.
CD44 ligation downregulates human c-jun promoter activity via AP-1 sites
To elucidate the molecular mechanisms underlying the downregulation of c-Jun expression by CD44 ligation, we performed promoter studies. U937 and HL60 cells were transiently transfected with different c-jun promoter/ luciferase constructs and then subjected to A3D8 treatment. Our results show that the full-length c-jun promoter (bp À1780/+731) activity was downregulated 14-fold after A3D8 treatment ( Figure 6 ). It was not a vector effect since A3D8 had no effect on pGL3, in which c-jun promoter constructs were subcloned. As a positive control for our promoter studies, we also show that TPA increases the c-jun promoter activity (data not shown). To map site(s) in the c-jun promoter responsible for the downregulation, a series of c-jun promoter deletion mutant-luciferase gene chimeric plasmids with variable ends (from bp À1780 to À63), (Wei et al., 1998) was also transiently transfected into the cells. The promoter activity of each construct (without any treatment) with respect to the full-length promoter activity is shown ( Table 2 ). The results show that the downregulation of cjun promoter activity is lost after deletion of the region between bp À1780 and À63 (with À63/+731 construct), where two AP-1 sites (bp À64 and À182) are located (Figure 6a, c) . The presence of the two AP-1 sites in the cjun promoter, a proximal (bp À64) and a distal (bp À182) one led us to further map the AP-1 site responsible for the downregulation. Upon deletion of the proximal (delpAP-1) or the distal (deldAP-1) AP-1 sites in the cjun promoter, we observed a similar downregulating effect, while the effect was lost upon deletion of both AP-1 sites (Figure 6b ). The loss of repression effect cannot be a simple activation because the promoter activity in the presence of A3D8 is the same as that of the promoter alone ( Figure 6b , last two bars), although in the presence of A3D8 antibody the activity of the promoter with two mutant AP-1 sites has a higher activity than either of the singly mutated constructs (Figure 6b , compare bars with A3D8 treatment). These results show that both AP-1 sites are important for the downregulation of c-jun promoter activity upon CD44 ligation with A3D8.
A3D8 treatment decreases c-Jun phosphorylation and JNK expression
The decreased transactivation property of c-Jun by A3D8 could be mediated through a change in the phosphorylation status of c-Jun. To investigate if A3D8 treatment of the cells caused decreased c-Jun phosphorylation, we performed immunoblot analyses of cell lysates from HL60 cells using a phospho-specific (Ser63) anti-c-Jun antibody (Figure 7) . No phosphorylated c-Jun was detected at 12 or 24 h after A3D8 treatment (Figure 7 , lanes 4 and 5), although c-Jun phosphorylation was detected at 6 h and in the controls (Figure 7, lanes 1-3) . Furthermore, our results showed that A3D8 treatment drastically decreased the expression of JNK1, ahead of (Figure 7b ). The effect seems to be JNK-specific since only an insignificant effect on ERK1 expression could be detected (Figure 7c ). These data suggest that inhibition of c-Jun expression by A3D8 results from inhibition of c-Jun phosphorylation via the JNK pathway. Taken together, our data indicate that inhibition of c-Jun/AP-1 activity may be the mechanism by which A3D8 inhibits the proliferation and causes cell cycle arrest in myeloid cells.
Overexpression of c-Jun in HL60 cells overcomes the proliferation-inhibiting effects of A3D8
To further characterize the role of c-Jun biologically, we overexpressed c-Jun in HL60 cells to investigate if the effects of proliferation inhibition and differentiation induction by A3D8 can be overcome. HL60 cells were transfected with pMV7-c-jun retroviral construct as described in the Materials and methods section. After selection of the cells in G418, they were kept in G418-free media with and without A3D8. We observed that the expression of CD71 was markedly increased in pMV7-c-jun-transfected cells as compared to vector alone ( Figure 8a ). Moreover, c-Jun overexpressing HL60 cells showed increased cell numbers (Trypan blue cell counting) as compared to cells containing vector alone over a period of 3 days (Figure 8b ). We could clearly observe a slow growth in vector (pMV7)-transfected cells under constant selection pressure, whereas pMV7-c-jun-transfected cells showed a higher growth rate under similar conditions. As a more direct measure of cell proliferation, we also performed bromodeoxyuridine (BrdU) incorporation assay. Our results clearly show that pMV7-c-jun-transfected cells incorporate more BrdU than pMV7-transfected cells and hence, the former have more proliferation potential than the latter (Figure 8c ). After 24 h posttransfection, the percentage of pMV7-c-jun-transfected cells showed >50% BrdU incorporation as compared to o10% in the control. It is important to mention here that c-Jun overexpression in HL60 cells did not lead to any cell death as determined by propidium iodide staining (data not shown). Thus, c-Jun expression and cell proliferation in fact, do correlate in myeloid leukemia HL60 cells. The expression of c-Jun was 25-fold higher in pMV7-c-jun-transfected cells as compared to the controls (Figure 8d, e) . Furthermore, we observed that A3D8 treatment of untransfected HL60 cells and the cells transfected with vector alone (pMV7) caused decreased proliferation and hence, decreased CD71 expression as compared to the isotype control (Figures 1 and 8e , panels i, ii). On the contrary, in HL60 cells overexpressing c-Jun (pMV7-c-jun), A3D8 treatment did not lead to any changes in CD71 expression as compared to the isotype control ( Figure 8e , panel iii). A similar pattern was observed with CD11b expression (Figure 8f ), although the differentiation-inducing ability of c-Jun in c-Jun overexpressing HL60 cells is not of the same extent as the proliferation-inducing ability. These results clearly indicate that downregulation of the proliferation promoting transcription factor c-Jun is a prerequisite for A3D8-mediated proliferation-inhibition in our settings. 
Discussion
In the present study, we investigated the effect of CD44 ligation by anti-CD44 MoAb A3D8 on the proliferation of myeloid leukemia cells and the underlying molecular mechanisms involved. Our results demonstrate that ligation of CD44 with A3D8 causes growth arrest and induces terminal differentiation of human myeloid leukemia cell lines HL60 and U937 through the downregulation of c-Jun expression via AP-1 sites (Figures 5  and 6 ). Furthermore, decreased JNK expression and a consequent decrease in c-Jun phosphorylation may be involved in A3D8-mediated downregulation of the c-Jun promoter activity (Figure 7) . The downregulation of cJun expression is a prerequisite for growth inhibitory effects of A3D8 since overexpression of c-Jun is able to prevent A3D8-mediated effects (Figure 8 ). We also show an induction of G0/G1 arrest by A3D8 (Figure 3 ), which is accompanied by induction of p21 and inhibition of pRb, Cdk2 and Cdk4 protein expression and Cdk activity ( Figure 4 ). Although our results show c-Jun inactivation as an important mechanism of A3D8-mediated growth arrest, we do not rule out other mechanisms by which A3D8 can block proliferation of myeloid leukemia cells. Our results revealed that CD44 ligation with A3D8 decreases the proliferation and leads to the induction of terminal differentiation of HL60 and U937 cells (Figures 1 and 2) . These results are consistent with previous reports (Charrad et al., 2002) . A G0/G1 arrest upon A3D8 treatment of HL60 cells (Figure 3 ) could be explained considering that an exit from the cell cycle is a prerequisite for growth arrest and cell differentiation. Consistent with this and other reports (Danova et al., 1990; Hunter and Pines, 1994; Horiguchi-Yamada et al., 1994; Jiang et al., 1994; Liebermann et al., 1995; Steinman et al., 1998) A3D8 treatment led to the induction of p21 and inhibition of Cdk4 and Cdk2 kinase activities (Figure 4) . Thus, increase of p21 and/or the decrease of Cdk2 and Cdk4 expression in HL60 upon A3D8 treatment are sufficient to inhibit kinase activity required for G0/G1 progression into the S phase. In correlation with decreased Cdk activity, the phosphorylation of Rb was also decreased upon A3D8 treatment suggesting a role of Cdk/Rb pathway in cell cycle arrest by CD44 signaling (Figure 4f ).
CD44 ligation with A3D8 markedly downregulated the expression of c-Jun both at mRNA and protein level ( Figure 5 ). The downregulation of c-Jun could be expected because of the decreased proliferation of these cells. The downregulation of c-jun upon A3D8 treatment was also observed in AML patient blasts ( Figure 5) . However, the effect of CD44 ligation on c-jun expression in AML patients is less prominent than in myeloid cell lines. This could be because of the difference in cytogenetic set up in different AML patients. Moreover, the requirement of c-Jun could differ in normal versus transformed cells, in tumor cells of different cell lineages, or in cells having undergone transformation via different mechanisms. Basal promoter activity (% of full-length c-jun)
The values represent the promoter activity of different c-jun promoter constructs used in this study with respect to the full-length c-jun promoter (À1780/+731) chosen as 100. The transfection efficiency was corrected by dividing the promoter luciferase activity by renilla luciferase activity To rule out the downregulating effects on c-Jun as a consequence of A3D8 toxicity, we also show that A3D8 treatment does not downregulate the expression of cFos nonspecifically. Transient transfections of c-jun promoter/luciferase constructs in myeloid cells revealed that both AP-1 sites are responsible for the downregulation of c-jun promoter activity by CD44 signaling (Figure 6 ). Our results also show that the expression of JNK is decreased upon A3D8 treatment, with a consequent decrease in the level of c-Jun phosphorylation, which is consistent with published reports (Figure 7 ) Minden et al., 1994;  CD44 signaling inactivates c-Jun AA Peer Zada et al Smeal et al., 1991) . We used JNK1 since it has been shown to preferentially bind c-Jun and phosphorylate c-Jun (Kallunki et al., 1994) . The role of other JNKs remains to be determined. The effect of A3D8 is JNK-specific because ERK expression is not changed under similar conditions. It is important to note here that c-Fos expression did not change upon A3D8 treatment (Figure 5f ). Fos is known to be regulated by the ERK pathway (Chou et al., 1992; Deng and Karin, 1994) . The decreased JNK expression and hence, c-Jun phosphorylation could in turn be because of the positive effect of A3D8 treatment on p21 protein level (Figure 4a ). It has been reported that interaction of p21 with JNK inhibits JNK activity (Shim et al., 1996; Patel et al., 1998) . Thus, it is conceivable that the inhibition of JNK by p21 may be the mechanism for the downregulation of c-Jun phosphorylation and hence, the transactivation potential of c-jun. A3D8-mediated proliferation-inhibition in HL60 cells was prevented by c-Jun overexpression (Figure 8e ), suggesting that c-Jun/AP-1 activity is one of the molecular targets downstream of CD44 signaling. BrdU incorporation, CD71 expression (Theil, 1990; Kuhn, 1994; Trayner et al., 1998) and Trypan blue cell counting were used as a measure of cell proliferation and clearly demonstrate that c-Jun in fact, increases the proliferation of myeloid cells. c-Jun overexpression had little effect on CD11b expression (Figure 8f ). In the context of the role of c-Jun in myeloid cell differentiation, this might seem surprising. However, the role of c-Jun in differentiation could be time limiting. It is important to mention here that the downregulation of c-Jun expression upon CD44 ligation is in accordance with our recent findings in which the transcription factor C/EBPa was shown to downregulate c-Jun expression to induce myeloid differentiation . In summary, it is thus, conceivable to propose a model (Figure 9 ) which shows that the downregulation of c-Jun expression along a pathway which involves inhibition of JNK by p21 resulting in decreased c-Jun phosphorylation and hence, decreased promoter activity concomitant with decreased cell cycle proteins may be an important mechanism for regulating CD44-mediated differentiation-induction and proliferation-arrest with A3D8. Our results provide a framework for further investigations and suggest that clarification of the mechanisms of regulation may reveal novel targets for antiproliferative and/or differentiation therapy in AML.
Materials and methods
AML patient samples
Peripheral blood or bone marrow specimens containing at least 80% leukemic blasts were collected on the occasion of initial diagnosis. The fresh samples were seeded at 1 Â 10 6 cells/ml and stimulated with 20 mg/ml A3D8. RNA isolation was performed using RNeasy Mini kit (Qiagen) at time points indicated in the figure legends and real-time PCR was performed for c-jun expression as described below. Control samples were either unstimulated or stimulated with isotype matched antibody (IgG1, Sigma and/or J173, Immunotech). Cytospin was also performed to investigate the differentiation inducing ability of A3D8 as previously reported (Charrad et al., 1999) .
Cell lines, antibodies and treatments
Human myeloid cell lines HL60 and U937 were obtained from DMSZ (Germany) and cultured in RPMI-1640 medium (PAN Biotech GMBH) supplemented with 2 mm glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin and 10% FBS (GIBCO-BRL, Eragny, France) at 371C with 5% CO 2 enrichment. The cells were suspended at 3 Â 10 5 cells/ml in 96-well tissue culture plates (Nunc) with 200 ml/well. Monoclonal anti-CD44 antibody, A3D8 (Sigma) was added at the final concentration of 20 mg/ml. All the control samples were either untreated or treated with 20 mg/ml isotype-matched antibody (IgG1, Sigma or J173, Immunotech). For direct immunofluorescence staining, fluorescein isothiocyanate (FITC) MoAbs to CD11b (FITC, immunotech, IgG1) and CD71 (FITC, DAKO, IgG1) were used.
Proliferation assay
To assess the proliferation state of cells after various treatments, MTT proliferation assay kit (Boehringer Mannheim, Germany) was used according to the manufacturer's instructions. Briefly, cells were incubated with or without A3D8 for 1-4 days in 96-well plates. A volume of 10 ml MTT labeling reagent (5 mg/ml) was added every day to each well and the plates were incubated at 371C for 4 h. The resulting formazon crystals were solubilized by adding 100 ml of solubilization buffer (10% SDS in 0.01 m HCl) per well and the plates were incubated at 371C overnight. The absorbance of the formazon measured at 575 nm was used to account for the proliferation state of cells. Trypan blue cell exclusion was also used to assess the cell viability and the cell number.
Morphological analysis of cellular differentiation
After various cell treatments, HL60 and U937 cells were cytocentrifuged on glass slides using a cytospin device (ShandonElliot, Paris, France). May-Gru¨nwald-Giemsa-stained cytospin smears were then analysed under light microscopy. The analysis was performed on 200-300 cells.
Cell cycle analysis and flow cytometry
To investigate the surface expression of myeloid differentiation and proliferation markers, FACS analysis was performed. HL60 and U937 cells (3 Â 10 5 cells/ml) were stimulated for 36 h with A3D8 (20 mg/ml) and then stained with FITC or PE labeled antibodies at a concentration of 10 mg/ml at 41C for 30 min and washed twice with FACS buffer (PBS, 3% FCS, 0.01% NaN 3 ). Fluorescence was then analysed on Coulter EPICS XL/XL-MCL SystemII Software. Data were collected after 5000 cell analysis (per sample) and the results shown as scatter diagrams or expressed as D-value which is calculated as Mean fluorescence intensity ðMFIÞ ratio ¼ Mean of sample stained with MoAb= mean of isotype control MoAb Then, the percentage of difference between MFI ratio of sample incubated with or without A3D8 was calculated, giving a D-value (Pisani et al., 1997) for each sample. The D-value for unstimulated control was arbitrarily chosen and that of stimulated sample expressed relative to it. Negative D-values indicate more MFI of stimulated sample than unstimulated and hence, implies increased expression of the particular marker. Similarly, positive D-values imply decreased expression of the marker. For the cell cycle analysis, cells with or without A3D8 treatment were centrifuged at 1500 r.p.m. for 3 min, washed with PBS and then the DNA was stained with 100 mg/ml propidium iodide for 30 min at 41C protected from light. The cells were then analysed with the FACScan (Beckton-Dickinson) for different cell populations.
RNA isolation and semiquantitative RT-PCR
Total RNA was isolated from 7 Â 10 5 cells before and after treatment with A3D8 (20 mg/ml) and IgG1 (20 mg/ml) using RNeasy Mini kit (Qiagen). RNA of 100 ng was used for firststrand cDNA synthesis in a 20 ml reaction with 10 Â RT buffer, dNTP (5 mm), RNasin (1 U/ml), oligo dT (1 mm) and the reaction was incubated at 371C for 90 min. Equal amounts of cDNA were taken for c-jun PCR amplification using a Qiagen kit. Aldolase was used as an internal control. Primers used for PCR amplification were for c-jun (Gene Bank Acc. no. J04111): forward primer 5 0 -ACTGCAAAGA TGGAAAC-GAC-3 0 (bp 1264-1283) and reverse primer 5 0 -AAAATGTTT GCAACTGCTGC-3 0 (bp 2235-2254); and for aldolase: forward primer 5 0 -AGCTGTCTG ACATCG CTCACCG-3 0 and reverse primer 5 0 -CACATA CTGG CAGCGC TTCAAG-3 0 . The PCR cycling program consisted of 30 cycles of 941C for 2 min, 551C for 1 min and 721C for 80 s using DNA thermal cycler (Perkin-Elmer). PCR products of B971 bp (cjun) and B580 bp (Aldolase) were separated by 1.2% agarose gel electrophoresis and visualized by ethidium bromide staining with UV irradiation.
Quantitative Real-time PCR in AML patient samples Real-time PCR for c-jun and for the housekeeping gene glucose-6-phosphate dehydrogenase (G6PD) was performed using the Light Cycler Technology (Roche Diagnostics, Mannheim, Germany). For amplification of G6PD, primers were used according to Emig et al. (1999) : G6PD-1 forward primer 5 0 -CCGGATCGACCACTACCTGGGCAAG-3 0 and G6PD-2 reverse primer 5 0 -GTTCCCCACGTACTGGC-CCAGGACCA-3 0 . c-jun was amplified using the primer set according to Kiaris et al (1999) . c-jun-1 forward primer 5 0 -GCATGAGGAACC GCATCGCTGCCTCCAAGT-3 0 and c-jun-2 reverse primer 5 0 -GCGACCAAGTCCTT CCCACTCGTGCACACT-3 0 . G6PD plasmid: pGdBBX, kindly provided by A Hochhaus, University of Mannheim was serially diluted to 10 000, 1000 and 100 fg and used as a standard curve. The procedure for Real-time PCR was essentially the same as described previously .
Immunoblot analysis
Total cellular protein was extracted from HL60 and U937 cells before and after A3D8 treatment and subjected to electrophoresis on 10% SDS-PAGE gels. The Western blotting procedure was performed and the blots detected with the ECL system as described previously . Anti-b-tubulin antibody (Boehringer, Mannheim) was used as internal loading control on the same blot after stripping. Immunoblot analysis was performed for c-Jun (anti-rabbit, sc-45), c-Fos (anti-rabbit polyclonal, sc-52), JunB (anti-mouse monoclonal IgG1, sc-8051), Cdk2 (anti-rabbit, sc-163), Cdk4 (anti-rabbit, sc-260), Cdk6 (anti-rabbit, sc-177), cyclin D1 (anti-rabbit, sc-718), p21 (anti-mouse, sc-817), pRb (anti-mouse monoclonal, sc-102) and phospho-specific Rb (anti-goat, pRb-Ser780, sc-12901). The other antibodies used for the Immunoblot analysis were JNK1 (anti-rabbit, sc-474), ERK1 (anti-rabbit, sc-94 Santa Cruz), phosphoc-Jun (anti-mouse monoclonal, sc-822 Santa Cruz) and b-tubulin (anti-rabbit, sc-9104). All the blots were quantified by densitometry (Aida 2.1 software program) and the results reported in relation to b-tubulin. Comparison of the differences in expression was done between isotype control and A3D8-treated samples. Unstimulated samples served as a reference for the basal level of expression.
Immunocomplex kinase assay
After the described treatments, HL60 cells were washed with cold PBS and RIPA lysates prepared at different time points. Lysates were collected by centrifugation for 30 min and protein concentrations were quantified by the Bradford assay (Bio-Rad Laboratories, Germany). Protein of 200 mg was incubated with 2 mg of anti-Cdk2 or anti-Cdk4 antibody at 41C for 2 h with rotation. Protein A agarose beads (20 ml) were then added and the incubation continued for another 2 h. Immunocomplex beads were washed twice with PBS buffer and three times with kinase buffer (150 mm NaCl; 1 mm EDTA; 50 mm Tris-HCl, pH 7.5; 10 mm MgCl 2 ; and 10 mm DTT). Kinase activity was assayed by incubating the beads at 371C for 30 min with 25 ml kinase buffer, 3 mg histone H1 (Upsdate, Germany; Cdk2) or Rb-fusion protein (Santa Cruz; Cdk4), 10 mm ATP, and 4 mCi [g-32P]ATP (3000 Ci/mmol). Samples were then boiled for 5 min in 2 Â sample buffer, electrophoresed through a 12% SDS-PAGE, dried, and phosphorylated histone H1 and Rb proteins were visualized by autoradiography and quantified by Aida 2.1 software program.
Reporter constructs and transient transfections
The human full-length c-jun promoter plus 731 bp of downstream sequences (À1780/+731) subcloned into the firefly luciferase vector pGL3, and deletion mutants in the proximal and distal AP-1 sites of the same construct used in this study were kindly provided by Wayne Vedeckis (Wei et al., 1998) . As an internal control plasmid for cotransfection assays, the pRL-0 construct driving the Renilla luciferase gene (Promega) was used as described . Transient transfections were performed with these constructs by using Effectene transfection reagent (Qiagen) in myeloid cells. Effectene allows transfections in the absence of serum, which was important to rule out any serum-induced fluctuations in c-jun promoter activity. The cells were transiently transfected with 1 mg c-jun promoter/luciferase constructs and pRL-0 plasmid per well of the six-well plates. At 18 h after transfection, A3D8 was added to the wells to a final concentration of 20 mg/ml for additional 6 h. Promoter activities were determined by measuring the luciferase activity with the Dual Luciferase Assay System (Promega). Firefly luciferase activities of different c-jun promoter constructs in pGL3 were normalized to the Renilla luciferase values of pRL-0 . Results are given as mean7s.d. of at least three different independent experiments.
Stable cell lines overexpressing c-Jun and BrdU incorporation
To generate cell lines overexpressing c-Jun, the retrovirusderived cDNA expression vector was used for the study. This vector, designated pMV7-c-jun was kindly provided by Dr Yaniv. The vectors are described elsewhere (Kirschmeier et al., 1988) . pMV7-c-jun and the empty vector pMV7 (lacking the c-Jun cDNA insert) were transfected into HL60 cells by electroporation (300 V/975 mF). After 24-48 h, the cells were transferred into selective medium containing 1 mg/ml G418 and analysed for CD71 expression and BrdU incorporation by flow cytometry. Trypan blue cell counting and PI staining was also performed at different time points. In addition to CD71 expression and cell counting, BrdU, a thymidine analogue which gets incorporated into cellular DNA was also used as a measure of cell proliferation in c-Jun overexpressing HL60 cells. The assay was performed by using in situ cell proliferation kit, FLUOS (Roche, Mannheim, Germany, cat. no. 1810740) according to the manufacturer's instructions. Briefly, after transfer into selection medium, HL60 cells (3 Â 10 5 cells/ml previously transfected with pMV7 and pMV7-c-jun) were incubated with 10 mm BrdU for 1 h at 371C in 5% CO 2 . The cells were then fixed in 70% ethanol in 50 mm glycine buffer, pH 2.0, washed in PBS, acid denatured (4 m HCl) and incubated with anti-BrdU-FLUOS antibody solution for 45 min at 371C in 5% CO 2 . The cells were then analysed by flow cytometry and the data presented as scatter diagrams. In a similar experiment, after 1 week in the selection medium, the cells transfected with pMV7 or pMV7-c-jun were then stimulated with A3D8 or IgG with a final concentration of 20 mg/ml. At 36 h after treatment with A3D8, the cells were analysed for CD11b and CD71 expression. The expression of c-Jun in c-Jun overexpressing HL60 cells was measured by Real-time PCR and Western blot analysis.
